MajorMucolytic; paracetamol overdose antidote; glutathione precursor×Second-generation antihistamine
Updated · Methodology
Mechanism
Acetylcysteine thins mucus: its free sulfhydryl group breaks the disulfide bonds in mucoproteins, which lowers mucus viscosity without increasing its volume (acetylcysteine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acetylcysteine SmPCs advise against combining acetylcysteine with cough suppressants or with substances that inhibit bronchial secretions, and give anticholinergics and antihistamines as examples. With these drugs, the thinned secretions may become harder to clear (acetylcysteine SmPCs, AEMPS). Desloratadine is a long-acting, non-sedating antihistamine that selectively blocks peripheral histamine H1 receptors and does not readily enter the central nervous system (desloratadine SmPC, European Medicines Agency, EMA). Its documents describe no anticholinergic effect and no effect on bronchial secretions, and none of the documents reports a study of this pair (desloratadine SmPC, EMA; desloratadine label, US Food and Drug Administration, FDA).
Symptoms
If secretions clear less well, the person finds it harder to cough up sputum (acetylcysteine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Early in treatment, acetylcysteine itself thins secretions and increases expectoration. In people with asthma or a history of bronchospasm, it may worsen airway obstruction or trigger bronchospasm (acetylcysteine SmPC, AEMPS). The most common adverse effects of desloratadine are fatigue, dry mouth and headache, and drowsiness is very rare (desloratadine SmPC, European Medicines Agency, EMA).
Management
Avoid the combination. The Spanish acetylcysteine summaries of product characteristics (SmPCs) advise against taking acetylcysteine with substances that inhibit bronchial secretions and list antihistamines among them without distinguishing between generations (acetylcysteine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Desloratadine belongs to the antihistamine group according to its own SmPC, although its documents describe no anticholinergic effect and no effect on bronchial secretions (desloratadine SmPC, European Medicines Agency, EMA). If the combination is used anyway, watch how well sputum clears. If the patient cannot cough up the thinned secretions, use postural drainage and bronchial suction (acetylcysteine SmPC, AEMPS). If bronchospasm occurs, stop acetylcysteine and treat the bronchospasm (acetylcysteine SmPC, AEMPS). If there is no improvement after 5 days of acetylcysteine or new symptoms appear, reassess the patient (acetylcysteine SmPC, AEMPS). Acetylcysteine is contraindicated in children under 2 years. In patients with asthma, a history of bronchospasm or severe respiratory failure, give it only after a separate assessment (acetylcysteine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Acetilcisteína – Fluimucil Forte 600 mg (nº registro 62663), sección 4.5 (2025)– AEMPS, CIMA, nº registro 62663 (Fluimucil Forte 600 mg comprimidos efervescentes, Zambon), revisión 09/2025, secciones 4.2, 4.3, 4.4, 4.5 y 5.1
- AEMPS: Ficha técnica: Acetilcisteína (nº registro 67763), sección 4.5 (2021)– AEMPS, CIMA, nº registro 67763 (Acetilcisteína Cinfa 600 mg comprimidos efervescentes EFG), revisión 10/2021, secciones 4.4 y 4.5
- EMA: Ficha técnica: Desloratadina – Aerius (EU/1/00/160), sección 5.1 (2026)– EMA, SmPC Aerius 5 mg comprimidos recubiertos con película (EU/1/00/160), texto en CIMA nº 00160009, consultado 19/10/2026, sin fecha de revisión en CIMA, secciones 4.5, 4.8 y 5.1
- FDA: Clarinex (desloratadine) prescribing information (2025)– FDA, DailyMed setid c671342e-69a2-4ca5-abc2-8166ed4240d4 (Organon LLC), revisión 05/2025 (versión 6, texto revisado 06/2021), secciones 6.1, 7 y 12.1